#31
|
||||
|
||||
Êîëëåãè, à risk ratio è relative risk - èäåíòè÷íûå ïîíÿòèÿ? Ñïàñèáî.
|
#32
|
|||
|
|||
|
#33
|
|||
|
|||
Âñåì ïðèâåò!
 î÷åðåäíîé ðàç ñòàëêèâàåøüñÿ ñ òåì, ÷òî â òûùó ðàç ïðîùå ñêàçàòü íà àãëèöêîì, ÷åì íàéòè àäåêâàòíóþ ôðàçó.... A recent phase III, randomized, noninferiority study compared overall survival (OS) of the standard regimen cisplatin plus gemcitabine (CG) versus cisplatin plus pemetrexed (CP) in 1725 chemonaive patients with advanced.... Ïîíÿòíî - õîòåëè äîêàçàòü ÷òî CP íå õóæå CG, íî êàê óäîáîâàðèìî ñêàçàòü ïî íàøåíñêè? :-( "äëÿ äîêàçàòåëüñòâà ñðàâíèìîé ýôôåêòèâíîñòè"? -------------------------------------------- Prespecified analyses demonstrated that .... Çàïëàíèðîâàíûé - ? |
#34
|
|||
|
|||
 ðóññêîì òî÷íîãî ýêâèâàëåíòà íåò, ïðîôåññîð Âëàñîâ, íàïðèìåð, ïðåäïî÷èòàåò òåðìèí "èñïûòàíèå íà íå ìåíüøóþ ýôôåêòèâíîñòü".
Íåäàâíåå ðàíäîìèçèðîâàííîå êëèíè÷åñêîå èñïûòàíèå ôàçû III ñ äèçàéíîì äëÿ âûÿâëåíèÿ íå ìåíüøåé ýôôåêòèâíîñòè ñðàâíèâàëî ñòàíäàðòíûé ðåæèì... |
#35
|
|||
|
|||
Îõ, íàãðóæó-òî âåäü....
using a fixed margin method for the hazard ratio (HR) of 1.17647. |
#36
|
|||
|
|||
Øèðå öèòàòó ìîæíî?
|
#37
|
|||
|
|||
|
|
#38
|
|||
|
|||
Ðàíäîìèçèðîâàííîå êëèíè÷åñêîå èñïûòàíèå ôàçû III íà íå ìåíüøóþ ýôôåêòèâíîñòü ñðàâíèâàëî îáùóþ âûæèâàåìîñòü ãðóïï ëå÷åíèÿ ñ èñïîëüçîâàíèåì ìåòîäà ôèêñèðîâàííîé ãðàíèöû îòíîøåíèÿ ðèñêîâ, ñîñòàâëÿâøåé 1.17647.
|
#39
|
|||
|
|||
Ñïàñèáî.
Ñóøó èçâèëèíû äàëüøå.... Median survival was estimated using the Kaplan–Meier method. Ìåäèàíà âûæèâàåìîñòè èëè "ìåäèàííàÿ/ñðåäíÿÿ âûæèâàåìîñòü"??? |
#40
|
|||
|
|||
|
#41
|
||||
|
||||
Êîëëåãè, à êàê íà ðóññêîì íàçûâàþò ýòè ñàìûå Forrest-plot èëè Forest-plot?
Äèàãðàììà Ôîðèñòà? äèàãðàììà "Äåðåâî ðåçóëüòàòîâ èíäèâèäóàëüíûõ èññëåäîâàíèé" ? Ñïàñèáî. Êàê ðàç ñòîëêíóëñÿ ñ íåîáõîäèìîñòüþ àäàïòàöèè ýòîãî òåêñòà â îòå÷åñòâåííóþ ìåòîäè÷êó.... |
#42
|
|||
|
|||
Òàê è ïèøóò - ãðàôèê ôîðåñò-ïëîò
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ëåñîâèäíûé ãðàôèê - íå äóìàþ ÷òî íóæíî òàê äîñëîâíî ïåðåâîäèòü. |
#43
|
|||
|
|||
Öèòàòà:
"Ãðàôèê ìåòà-àíàëèçà" - è âñåõ äåëîâ . |
#44
|
||||
|
||||
Ñïàñèáî. Â "ëåñ" çàëåçàòü íå áóäó. À ÷òî òàêîå
random-effects-model meta-analysis of logit transformed data? |
#45
|
|||
|
|||
Ìåòà-àíàëèç ñ èñïîëüçîâàíèåì ìîäåëè ñëó÷àéíûõ ýôôåêòîâ (ñ èñïîëüçîâàíèåì ëîãèò-ïðåîáðàçîâàííûõ äàííûõ). Òî, ÷òî â ñêîáêàõ - èçáûòî÷íîå îáúÿñíåíèå è åãî ïðèâîäèòü íå íóæíî, ìîäåëü àâòîìàòè÷åñêè ïðåäïîëàãàåò ëîã-òðàíñôîðìàöèþ.
|